Is Neurotech's Search For Highly-Focused Targets Holding Up Drug Development In The Field?
This article was originally published in The Pink Sheet Daily
Executive Summary
The issue of whether a start-up should know its compound's mechanism of action before it knocks on a VC's door became an ongoing topic of conversation at the Neurotech Investing conference in Boston.